StockData
Genmab A/S logo

Genmab A/S (GMAB) shareholders

GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Score 0/30
$51.96+0.39 (+0.76%)

Close on Nov 17, 2026

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
102M of 64M shares
Institutional holders
290
50 new, 30 sold out
Net institutional buying
20M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
BlackRock, Inc.3,707,3465.60%13G (passive) amendmentMar 31, 2025
Darwin Global Management, Ltd.
Joint filing with Dr. Abhishek Trehan (5.90%), Darwin Global Master Fund, Ltd. (5.70%)
3,668,3105.90%13G (passive)Sep 28, 2026
Orbis Investment Management Ltd3,320,6955.30%13G (passive) amendmentJun 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of GMABValueChange% of portfolio
Paradigm Biocapital Advisors LP13,133,13120.40%$360.77M+5,165,2956.76%
Orbis Allan Gray Ltd11,368,16117.66%$312.28M−1,557,4171.07%
Alliancebernstein L.P.8,644,87713.43%$231.94M−912,2720.08%
Deerfield Management Company, L.P. (Series C)6,865,00010.66%$188.58M+4,403,0001.97%
Deep Track Capital, LP5,650,0008.78%$155.21M+1,986,7502.26%
Arrowstreet Capital, Limited Partnership4,975,3247.73%$136.67M–0.06%
BlackRock, Inc.4,671,2527.26%$128.32M+134,6870.00%
Sofinnova Investments, Inc.4,045,2156.28%$111.12M+3,292,9545.74%
Renaissance Technologies LLC3,517,8505.46%$96.64M−896,7000.13%
Two Sigma Investments, LP3,506,8435.45%$96.33M+1,167,4110.07%
Harding Loevner LP3,086,3184.79%$86.90M−145,2830.82%
First Trust Advisors LP2,756,5224.28%$75.72M+295,1800.04%
Citadel Advisors LLC2,475,9913.85%$68.02MNew0.01%
Qube Research & Technologies Ltd1,689,2842.62%$46.40M+1,011,9380.04%
Morgan Stanley1,630,1612.53%$44.78M−554,5400.00%
Federated Hermes, Inc.1,449,3762.25%$39.81M+197,7860.06%
Goldman Sachs Group Inc1,279,2311.99%$35.14M+347,9720.00%
Franklin Resources Inc1,202,9231.87%$33.04M+9,7780.01%
Pictet Asset Management Holding SA1,065,9271.66%$29.28M−11,5440.03%
UBS Group AG961,0531.49%$26.40M+662,9210.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026290102M100.0%50 / 102100 / 3026M5M
Q1 202627582M100.0%44 / 10595 / 5918M8M
Q4 202529373M100.0%77 / 12155 / 2917M5M
Q3 202525362M96.2%66 / 9963 / 2812M14M
Q2 202521864M99.2%38 / 8274 / 3610M11M
Q1 202522065M100.0%37 / 9267 / 4114M9M
Q4 202422961M94.5%51 / 7675 / 4218M9M
Q3 202422452M81.3%30 / 9865 / 2410M1M
Q2 202422049M75.8%27 / 6894 / 344M5M
Q1 202422750M77.6%42 / 8872 / 405M3M
Q4 202322648M74.3%43 / 54103 / 4610M9M
Q3 202323448M73.8%41 / 9656 / 218M2M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

44 funds held GMAB in Q2 2026, 54% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of GMABValue% of fundAs of
iShares Biotechnology ETF3,701,0955.75%$101.67M1.12%Jun 30, 2026
First Trust NYSE Arca Biotechnology Index Fund2,686,6004.17%$73.80M2.62%Jun 30, 2026
Ab Large Cap Growth Fund Inc1,692,4122.63%$46.49M0.20%Jun 30, 2026
Federated Hermes Kaufmann Fund520,7000.81%$15.03M0.31%Jul 31, 2026
Avantis International Equity ETF512,6630.80%$13.50M0.08%May 31, 2026
Federated Hermes Kaufmann Small Cap Fund350,0000.54%$10.10M0.35%Jul 31, 2026
Federated Hermes International Leaders Fund343,7710.53%$9.05M0.59%May 31, 2026
Tax-Managed U.S. Large Cap Fund342,3440.53%$9.88M0.08%Jul 31, 2026
Mercer Non-US Core Equity Fund179,6760.28%$4.94M0.10%Jun 30, 2026
SA AB Growth Portfolio161,3980.25%$4.66M0.26%Jul 31, 2026
Tema Oncology ETF158,8610.25%$4.18M2.37%May 31, 2026
LVIP AllianceBernstein Large Cap Growth Fund157,5660.24%$4.33M0.27%Jun 30, 2026
Timothy Plan International Fund137,0000.21%$3.76M1.59%Jun 30, 2026
AB Large Cap Growth Portfolio105,2770.16%$2.89M0.28%Jun 30, 2026
U.S. Strategic Equity Fund104,2930.16%$3.01M0.10%Jul 31, 2026

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
10M shares short
Days to cover
1.2
At 8M shares a day
Change since last report
+46.4%
From 7M shares
Short volume, 20 days
49.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Genmab A/S's stock actually held short. Settlement fails (shares not delivered on time) peaked at 36,255 shares on Oct 1, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Klimovsky Judith V.
Officer
Nov 10, 20261,265$704.33KNov 10, 2026Stock Award
Klimovsky Judith V
Director
Jun 17, 20251,300$67.20KJun 17, 2025Stock Award
Klimovsky Judith V
Officer
Mar 1, 20241,200$330.00KMar 1, 2024Stock Award

See a number that looks wrong?